

The Bethesda
Handbook of
Clinical
Oncology

中文翻译版

贝塞斯达
临床肿瘤学手册

原书第4版

主编 Jame Abraham
James L. Gulley
Carmen J. Allegra
主译 束永前 刘连科



科学出版社

中文翻译版

贝塞斯达临床肿瘤学手册

The Bethesda Handbook of Clinical Oncology

原书第4版

主编 Jame Abraham
James L. Gulley
Carmen J. Allegra

主译 束永前 刘连科

科学出版社

北京

图字: 01-2015-4013 号

内 容 简 介

本书由美国国家癌症研究所及其他权威机构的医生编著而成, 内容几乎涵盖了所有恶性肿瘤。本书第4版侧重于介绍临床实践内容, 重点为读者介绍每种肿瘤的诊断和治疗方案, 以及最新临床试验结果, 并在前三版的基础上增加了临床遗传学及诊断驱动的癌症个性化治疗等内容, 在大部分章节末增加了选择题。

本书内容以表格、流程图等多种简明、直观的形式呈现, 便于查阅, 可作为临床肿瘤科医师、研究生及其他相关人员的参考书。

图书在版编目(CIP)数据

贝塞斯达临床肿瘤学手册: 原书第4版/(美) 詹姆·亚伯拉罕 (Jame Abraham) 等主编; 束永前等译. —北京: 科学出版社, 2016. 9

书名原文: The Bethesda Handbook of Clinical Oncology (Fourth Edition)

ISBN 978-7-03-049517-4

I. 贝… II. ①詹… ②束… III. ①肿瘤学-手册 IV. R73-62

中国版本图书馆 CIP 数据核字 (2016) 第 182111 号

责任编辑: 沈红芬 马晓伟 / 责任校对: 张怡君 赵桂芬

责任印制: 肖 兴 / 封面设计: 陈 敬

Jame Abraham, etc: The Bethesda Handbook of Clinical Oncology, 4th ed

ISBN: 978-1-4511-8758-8

Copyright © 2014 by Lippincott Williams & Wilkins, a Wolters Kluwer business. All rights reserved.

This is a Chinese translation published by arrangement with Lippincott Williams & Wilkins/Wolters Kluwer Health, Inc., USA.

本书限中华人民共和国境内(不包括香港、澳门特别行政区及台湾)销售。

本书封面贴有 Wolters Kluwer Health 激光防伪标签, 无标签者不得销售。

本书中提到一些药物的适应证、不良反应和剂量, 它们可能需要根据实际情况进行调整。读者须仔细阅读药品包装盒内的使用说明书, 并遵照医嘱使用, 本书的作者、译者、编辑、出版者和销售商对相应的后果不承担任何法律责任。

科学出版社出版

北京东黄城根北街16号

邮政编码: 100717

<http://www.sciencep.com>

中国科学院印刷厂印刷

科学出版社发行 各地新华书店经销

*

2016年9月第 一 版 开本: 890×1240 A5

2016年9月第一次印刷 印张: 30 5/8

字数: 1 000 000

定价: 148.00 元

(如有印装质量问题, 我社负责调换)

《贝塞斯达临床肿瘤学手册》

(原书第4版)

翻译人员

主 译 束永前 刘连科

译 者 (按姓氏汉语拼音排序)

陈佳艳 陈丽娟 陈晓锋 崔诗允

杜 斌 顾艳宏 郝卫文 黄 香

蒋书娣 金时代 李 薇 刘连科

刘怡茜 倪 芳 邱天竹 沈 华

束永前 孙 婧 王同杉 吴 昊

许佳丽 朱程君

CONTRIBUTORS

Jame Abraham, MD, FACP *Director, Breast Oncology Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio*

Bamidele A. Adesunloye, MD, MS *Senior Clinical Fellow, Medical Oncology Service, National Cancer Institute, National Institutes of Health, Bethesda, Maryland*

Sanjiv S. Agarwala, MD *Professor of Medicine, Temple University; Chief, Oncology and Hematology, St. Luke's Cancer Center, Bethlehem, Pennsylvania*

Sairah Ahmed, MD *Assistant Professor of Medicine, Division of Cancer Medicine, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M. D. Anderson Cancer Center, Houston, Texas*

Carmen J. Allegra, MD *Professor and Chief, Division of Hematology and Oncology, Associate Director for Clinical and Translational Research, Shands/University of Florida Cancer Center, University of Florida, Gainesville, Florida*

Lukas C. Amler, PhD *Director, Oncology Biomarker Development, Genentech, Inc., South San Francisco, California*

Christina M. Annunziata, MD, PhD *Investigator, Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland*

Andrea B. Apolo, MD *Assistant Clinical Investigator, Head, Bladder Cancer Research Program, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland*

Philip M. Arlen, MD *Attending Physician, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland*

Anne Berger, MSN, MD *Senior Clinician, Pain and Palliative Care Service, National Institute of Health Clinical Center, National Institutes of Health, Bethesda, Maryland*

Philippe C. Bishop, MD *Vice President, Product Development Oncology, Angiogenesis Franchise Head, Genentech, Inc., South San Francisco, California*

Christopher Bowden, MD *Vice President, Global Signing Franchise Head, Product Development, Oncology, Genentech, South San Francisco, California*

Oscar S. Breathnach, MB, FRCPI *Consultant Medical Oncologist, Clinical Investigator, Beaumont Hospital, Connolly Hospital, Royal College of Surgeons, ICORG Dublin, Ireland*

Christina Brzezniak, DO *Clinical Fellow, Hematology and Oncology, Walter Reed National Military Medical Center, Bethesda, Maryland*

Mauricio E. Burotto Pichún, MD *Senior Clinical Fellow, Medical Oncology Service, National Cancer Institute, National Institutes of Health, Bethesda, Maryland*

Eric G. Bush, MD, MBA, RPh *Medical Director, Frederick Memorial Hospital Pain and Palliative Care Service; Medical Director, Hospice of Frederick County; Chairman, Ethics Committee, Frederick Memorial Hospital, Frederick, Maryland*

Jon Cardinal, MD *Assistant Professor of Surgery, West Virginia University Hospital, Morgantown, West Virginia*

George L. Carter, MMS, PA-C *Physician Assistant, Medical Oncology Service, National Cancer Institute, National Institutes of Health, Bethesda, Maryland*

Ellie E. Chan, MD *Assistant Professor of Medicine, Division of Hematology and Oncology, University of California, San Francisco, Fresno Medical Education, California*

Bruce D. Cheson, MD *Professor of Medicine, Head of Hematology; Deputy Chief, Division of Hematology-Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC*

Richard W. Childs, MD *Senior Investigator, Hematology Branch, National Heart Blood and Lung Institute, National Institutes of Health, Bethesda, Maryland*

Deborah Citrin, MD *Investigator, Radiation Oncology Service, Center for Cancer*

Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Barbara A. Conley, MD *Associate Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Rockville, Maryland*

David P. Cosgrove, MB, BCh *Assistant Professor, Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland*

Michael Craig, MD *Associate Professor of Medicine, Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, West Virginia*

Aaron Cumpston, PharmD *Pharmacy Clinical Specialist, Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, West Virginia*

Brendan Curley, DO, MPH *Fellow, Section of Hematology/Oncology, Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, West Virginia*

William L. Dahut, MD *Clinical Director, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland*

Alexandre Buckley de Meritens, MD *Senior Fellow Molecular Signaling Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland*

land

Suzanne G. Demko, PA-C Clinical Team Leader, Neuro-Oncology, Pediatric Oncology and Rare Tumors Group, Division of Oncology Products 2, Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, U. S. Food and Drug Administration, Silver Spring, Maryland

Marnie G. Dobbin, MS, RD Clinical Research Dietitian, Clinical Research Center, National Institutes of Health, Bethesda, Maryland

Mark K. Doherty, MB BCh BAO Consultant, University College Hospital Galway, Galway, Ireland

Jennifer M. Duff, MD Fellow, Division of Hematology and Oncology, University of Florida Health Cancer Center, Gainesville, Florida

Austin Duffy, MB, MRCPI Staff Clinician, Gastrointestinal Malignancies Section, Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Kieron Dunleavy, MD Staff Clinician, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Daniel E. Elswick, MD Assistant Professor, Director, Psychosocial Oncology Services, Department of Behavioral Medicine and Psychiatry, West Virginia University, Morgantown, West Virginia

Sharon Romano Fitzgerald, MD Fellow, Gynecologic Oncology, Walter Reed National Military Medical Center and Medical

Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
Sheryl B. Fleisch, MD Psychosomatic Medicine Fellow, Department of Psychiatry, University of North Carolina, Chapel Hill, North Carolina

Juan C. Gea-Banacloche, MD Staff Clinician, Infectious Diseases, Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Thomas J. George, Jr., MD, FACP Associate Professor, Director, Gastrointestinal Oncology Program, Division of Hematology and Oncology, University of Florida Health Cancer Center, Gainesville, Florida

Giuseppe Giaccone, MD, PhD Chief, Medical Oncology Branch; Head, Thoracic Oncology Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Govardhanan Nagaiah, MD Attending, Medical Oncology/Hematology New Mexico Cancer Center, Albuquerque, New Mexico

Ann W. Gramza, MD Medical Oncologist, Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Tim F. Greten, MD Chief, Gastrointestinal Cancer Section, Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

James L. Gulley, MD, PhD, FACP Chief, Medical Oncology Service, Center for Cancer Research, National Cancer Institute

te, National Institutes of Health Bethesda, Maryland, Formerly of Emory University School of Medicine, And Loma Linda University School of Medicine

Karl E. Haglund, MD, PhD Assistant Clinical Investigator, Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Mehdi Hamadani, MD Associate Professor of Medicine, Division of Hematology & Oncology, Medical College of Wisconsin & CIBMTR, Milwaukee, Wisconsin

Chad A. Hamilton, MD, Lt Col, USAF, MC Chief, Gynecologic Oncology Service; Co-Director, DOD Gynecologic Cancer Translational Research Center, Walter Reed National Military Medical Center, Bethesda, Maryland

Garrett M. Hampton, PhD Senior Director, Oncology Biomarker Development, Genentech, Inc., South San Francisco, California

Hannah W. Hazard, MD, FACS Assistant Professor of Surgery, Chief of Surgical Oncology, Assistant Dean for Admissions, West Virginia University School of Medicine, West Virginia

Christopher Ryan Heery, MD Staff Clinician, Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Upendra P. Hegde, MD Associate Professor of Medicine, Associate Director of Cutaneous Melanoma Program, University of Connecticut Health Center, Neag Compre-

hensive Cancer Center, Farmington, Connecticut

Lee J. Helman, MD Scientific Director for Clinical Research, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Joleen M. Hubbard, MD Assistant Professor, Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota

Thomas E. Hughes, PharmD, BCOP Clinical Pharmacy Specialist, Pharmacy Department, Clinical Research Center, National Institutes of Health, Bethesda, Maryland

Geraldine Jacobson, MD, MPH, MBA, FACR Chair, Professor, Department of Radiation Oncology, West Virginia University School of Medicine, WVU Healthcare, Morgantown, West Virginia

Elaine S. Jaffe, MD Chief, Hematopathology Section Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Abraham S. Kanate, MD Assistant Professor of Medicine, Section of Hematology/Oncology, Marry-Babb Randolph Cancer Center, Morgantown, West Virginia

Uzer Khan, MD Academic Chief Resident, Department of Surgery, West Virginia University Hospitals, Morgantown, West Virginia

Hung T. Khong, MD Associate Professor, Division of Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah

Joseph Woong Kim, MD Senior Clinical Fellow, Medical Oncology Service, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Stephen Ko, MD Instructor, Department of Radiation Oncology, Mayo Clinic Florida, Jacksonville, Florida

David R. Kohler, PharmD Staff Scientist, Clinical Center Pharmacy Department, National Institutes of Health, Bethesda, Maryland

Elise C. Kohn, MD Head, Women's Cancers Clinic; Head, Molecular Signaling Section; Senior Investigator, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Teri Kreisl, MD Staff Clinician, Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Shaji K. Kumar, MD Professor of Medicine, Consultant, Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota

Jung-min Lee, MD Assistant Clinical Investigator, Women's Cancers Clinic, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Gregory D. Leonard Consultant, University College Hospital Galway, Galway, Ireland

W. Marston Linehan, MD Chief, Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Na-

tional Institutes of Health, Bethesda, Maryland

Ravi A. Madan, MD Assistant Clinical Investigator, Laboratory of Tumor Immunology and Biology, Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Midhun Malla, MD, MBBS Internal Medicine, St. Joseph Hospital and Medical Center, Phoenix, Arizona

Patrick J. Mansky, MD Medical Oncologist, Medical Director, Clinical Research, The Cancer Team at Bellin Health, Green Bay, Wisconsin

Clifton Mo, MD Hematology/Oncology Staff Physician, Department of Medicine, Walter Reed National Military Medical Center, Bethesda, Maryland

Manish Monga, MD Assistant Professor of Medicine, Section of Hematology/Oncology; Medical Director, Clinical Trial Research Unit, Mary Babb Randolph Cancer Center, West Virginia University Hospital, Morgantown, West Virginia

Dominic H. Moon, MD, MBBS National Institutes of Health, Medical Research Scholar Program Fellow, National Institutes of Health, Bethesda, Maryland

Jarushka Naidoo, MB BCH BAO MRCPI Medical Oncology Specialist Registrar, Beaumont Hospital, Connolly Hospital, Royal College of Surgeons, ICORG, Dublin, Ireland

Julie Nangia, MD Assistant Professor, Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas

Anne M. Noonan, MB BCh BAO, MSc, *MRCPI Investigator, Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland*

Maryland Pao, MD *Clinical Director, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland*

Muzaffar H. Qazilbash, MD *Professor of Medicine, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas*

Sarah Read, MD, MHS *Director, Therapeutics Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland*

Mark Roschewski, MD *Staff Clinician, Lymphoma Therapeutics Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland*

Donald L. Rosenstein, MD *Professor, Departments of Psychiatry and Medicine; Director, Comprehensive Cancer Support Program, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina*

Inger Lerra Rosner, MD *Director, Urology Oncology; Associate Director, Center for Prostate Disease Research; Assistant Professor of Surgery, USUHS, Walter Reed National Military Medical Center, Bethesda, Maryland*

Kerry Ryan, MPH, MS, PA-C *Physician Assistant, Medical Oncology Branch, Na-*

tional Cancer Institute, National Institutes of Health, Bethesda, Maryland

Yogen Saunthararajah, MD *Staff, Hematologic Malignancies and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio*

Nilay A. Shah, MD *Fellow, Section of Hematology/Oncology, Department of Medicine, West Virginia University Hospital, Morgantown, West Virginia*

Nishith K. Singh, MD *Clinical Fellow, Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland*

Preet Paul Singh, MBBS *Fellow in Hematology/Oncology, Mayo Clinic, Rochester, Minnesota*

Ramaprasad Srinivasan, MD, PhD *Head, Molecular Cancer Section, Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland*

Lindsay C. Stansfield, PharmD, BCPS *Oncology Pharmacy Resident, Pharmacy Department, National Institutes of Health Clinical Center, Bethesda, Maryland*

Michael P. Stany, MD *Assistant Professor, Uniformed Services University of the Health Sciences, Bethesda, Maryland*

Annie Su, MD *Fellow, Hematology/Oncology, Baylor College of Medicine, Houston, Texas*

Anish Thomas, MBBS, MD *Senior Clinical Fellow, Medical Oncology Service, National Cancer Institute, National Institutes of Health, Bethesda, Maryland*

Quoc Truong, MD *Clinical Assistant Professor of Hematology/Oncology, Cancer Center of Kansas, University of Kansas Medical Center, Wichita, Kansas*

Chaitra S. Ujjani, MD *Assistant Professor of Medicine, Division of Hematology-Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC*

Carter Van Waes, MD, PhD *Chief, Head and Neck Surgery Branch; Clinical Director, National Institute on Deafness and Oth-*

er Communication Disorders; Senior Investigator, Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Wyndham Wilson, MD, PhD *Chief, Lymphoma Therapeutics Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland*

Sarah Zentack, ScM, CGC *Instructor, Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas*

前 言

《贝塞斯达临床肿瘤学手册》是一部简洁、精练的综合性参考书，适合于日常工作中繁忙的临床医师使用。本书由在美国国家癌症研究所和美国国立卫生研究院、霍普金斯、梅奥诊所和克利夫兰诊所工作的医生，以及其他学术机构的学者共同编写。由于篇幅限制，本书涉及病因学、病理生理学和流行病学的相关内容较少，而着重于实际临床信息的介绍。为了使内容更为切题，本书避免了长篇累牍式的叙述，取而代之的是更多的表格、图片、流程图和缩略语。

《贝塞斯达临床肿瘤学手册》并不是一本内容极为详尽、包含病理生理和复杂肿瘤患者诊治方案解析的肿瘤学理论专著，而是为读者提供各种疾病治疗方法的精练介绍，包括诊断、用药剂量、疗程等，是一本适合肿瘤科医生、肿瘤科研究生、住院医师、学生、肿瘤科护士和健康管理者参考的独特的、有价值的、便于阅读的手册。

自从13年前本书第1版出版以来，肿瘤学领域发生了巨大变化。在第4版中，我们对所有章节做了更新，并增加了两个新的章节：“临床遗传学”和“诊断驱动的癌症个性化治疗”。此外，我们在大多数章节编写了多选题，以增强学习体验，帮助临床医生准备资格考试。

我们一如既往地努力获取这一领域的最新进展，并虚心接受读者的反馈意见来完善本书。我们希望每个需要了解肿瘤概况的读者都能将《贝塞斯达临床肿瘤学手册》视为一种必不可少的资源。

Jame Abraham

James L. Gulley

Carmen J. Allegra

目 录

第一部分 头 颈 部

第 1 章 头颈部癌	1
------------------	---

第二部分 胸 部

第 2 章 非小细胞肺癌	39
第 3 章 小细胞肺癌	58

第三部分 消 化 系 统

第 4 章 食管癌	73
第 5 章 胃癌	88
第 6 章 胆道肿瘤	112
第 7 章 原发性肝癌	129
第 8 章 结直肠癌	143
第 9 章 胰腺癌	171
第 10 章 肛管癌	180
第 11 章 其他胃肠道肿瘤	201

第四部分 乳 腺

第 12 章 乳腺癌	217
------------------	-----

第五部分 泌尿生殖系统

第 13 章 肾细胞癌	250
-------------------	-----

第 14 章	前列腺癌	269
第 15 章	膀胱癌	294
第 16 章	睾丸癌	309

第六部分 妇 科 肿 瘤

第 17 章	卵巢癌	329
第 18 章	子宫内膜癌	343
第 19 章	宫颈癌	356
第 20 章	外阴癌	373

第七部分 肌肉骨骼系统

第 21 章	骨肉瘤和恶性肿瘤	382
--------	----------------	-----

第八部分 皮 肤

第 22 章	皮肤癌和黑色素瘤	398
--------	----------------	-----

第九部分 血液系统恶性肿瘤

第 23 章	急性白血病	428
第 24 章	慢性淋巴细胞白血病	449
第 25 章	慢性髓系细胞白血病	459
第 26 章	慢性骨髓增生性肿瘤	469
第 27 章	多发性骨髓瘤	480
第 28 章	非霍奇金淋巴瘤	506
第 29 章	霍奇金淋巴瘤	525
第 30 章	造血干细胞移植	540

第十部分 其他恶性肿瘤

第 31 章	原发灶不明的恶性肿瘤	558
--------	------------------	-----

第 32 章 中枢神经系统肿瘤	569
第 33 章 内分泌肿瘤	592

第十一部分 支持治疗

第 34 章 造血生长因子	612
第 35 章 肿瘤感染并发症	624
第 36 章 肿瘤急症和副肿瘤综合征	653
第 37 章 肿瘤领域的精神类药物治疗	671
第 38 章 呕吐的处理	686
第 39 章 医学营养治疗	727
第 40 章 疼痛和姑息治疗	741
第 41 章 中心静脉通路装置	749

第十二部分 常用诊间操作及其他

第 42 章 肿瘤内科操作	762
第 43 章 诊断驱动的癌症个性化治疗	773
第 44 章 放射肿瘤学的基本原则	783
第 45 章 临床遗传学	792
第 46 章 抗癌药物	807
附录 1 体能状况评分标准	961
附录 2 复习题答案	962

第一部分

头 颈 部

第1章 头颈部癌

Carter Van Waes, Karl E. Haglund, and Barbara A. Conley

一、流行病学

全世界头颈部鳞状细胞癌每年发病超过 500 000 例,美国为每年 40 000 ~ 60 000 例,头颈部鳞状细胞癌占有所有新发癌症的 3% ~ 5%, 约占所有癌症死亡者的 2%。大多数患者在 50 岁以上,且发病率随着年龄的增大而增加;男女发病率之比为 2 : 1 ~ 5 : 1。年龄调整发病率在黑人男性中最高,而且,各分期中非裔美国人生存期总体上低于白种人。自 1975 年以后,头颈部肿瘤死亡率已经呈下降趋势,尤其在过去的十年中死亡率更加迅速地下降。90% 的头颈部癌为鳞状细胞癌。在美国,头颈部癌最常见的发生部位为口腔、咽、喉和下咽。鼻腔、鼻窦、鼻旁窦癌,唾液腺恶性肿瘤,以及各种肉瘤、淋巴瘤和黑色素瘤较为少见。

二、危险因素

过量饮酒可使患头颈部鳞癌的风险增加 2 ~ 6 倍,吸烟使风险增加 5 ~ 25 倍,根据性别、种族和吸烟量的不同而不同。两种因素共同作用可使患病风险增加 15 ~ 40 倍。无烟烟草和鼻烟均与口腔癌相关。使用无烟烟草、咀嚼槟榔或不伴有烟草和熟石灰(常见于亚洲许多地区和非洲的一些地区),与癌前病变及口腔鳞癌有关。

已在头颈部癌患者中描述了多灶性黏膜异常(区域性癌变)。在该区域有癌症病史的患者中,继发性头颈部癌、肺癌、食管癌的每年风险为 2% ~ 6%。那些持续性吸烟者的发病风险最高。在初发头颈部鳞癌的幸存者中,第二原发肿瘤是其主要的死亡危险因素。

在几乎所有的非角化和未分化的鼻咽癌中已检测到 EB 病毒 (EBV)，但在鼻咽鳞癌上不太一致。人乳头瘤病毒 (HPV) 感染与高达 70% 的口咽部和扁桃体癌，以及一些喉和鼻咽鳞癌相关。HPV 阳性癌的发生率在一些国家似乎在增加，而且 HPV 阳性在不吸烟患者中更常见。DNA 修复紊乱（如范科尼贫血、先天性角化不良）及器官移植使用免疫抑制剂者也与头颈部鳞癌的风险增加有关。

三、筛 查

由于发病率低及缺乏敏感性研究，美国预防工作组 (U. S. Preventive Task Force) 没有推荐在一般人群中常规筛查口腔癌。但他们推荐戒烟咨询和限制饮酒。美国癌症学会推荐在内科或口腔科预约中进行口腔检查。口腔检查包括所有黏膜区的检查、评估舌活动范围、双手触诊口底、舌触诊，评估牙齿健康。对于存在危险因素 [如吸烟和 (或) 饮酒]，以及有可疑症状的个体，必须进行仔细的头颈部检查。任何局部/区域性的不适主诉都需要评估，尤其对那些症状持续超过 4 周或对疑似感染治疗后症状持续存在的患者。

四、预防和化学预防

预防头颈部肿瘤的最重要措施是戒烟和限制乙醇摄入。由于 HPV 相关的头颈部癌症的风险与有多个性伴侣相关，安全性行为的教育也是有帮助的。对于青少年应考虑预防性地给予 HPV 疫苗，该治疗目前已被美国食品和药品管理局 (FDA) 批准用于预防女性宫颈癌 (二价或四价疫苗) 和男性生殖器疣 (四价疫苗)，以及预防肛门癌前病变 (四价疫苗)。目前正在收集疫苗接种对于 HPV 相关性头颈部癌发生率影响的资料。

口腔、咽、喉等部位发生癌前病变可表现为白斑 (不易刮去的、而且没有其他明显原因的白色斑片) 或红斑 (质脆红色或斑点状病变)。这些病变需要活检，以及潜在的切除。不伴异型增生的白斑进展到癌症的风险大约为 4%。然而，重度异型增生或黏膜红斑进展为癌症的风险可达 40%。

目前，对于有头颈部鳞癌风险的患者尚无有效的化学预防方法。最近的一项 PPAR 激动剂——吡格列酮试验显示，在约 80% 的受试者中出